Frontlight ResearchEarly access
Taking peoplePhase 2
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Burkina Faso, Côte d’Ivoire, Gabon, Ghana, Kenya, and Uganda12 sites in 6 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 327 people, planned
- Started
- 23 Jan 2024
- Planned end
- 23 Jun 2026
- Type of study
- Interventional, 10 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- INE963
- KAE609 (Cipargamin)
- SoC (Coartem)
- KLU156
- Record updated
- 30 July 2025
Who can take part
- Age
- 2 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Male and female patients ≥18 years of age for Part A, ≥12 years of age for Part B and 2 to <12 years of age for Part C at screening
- Patients must have acute uncomplicated P. falciparum malaria mono infection at screening confirmed by a parasite count between 5,000 to 150,000 asexual parasite count/μl of blood for P. falciparum for Part A and between 1,000 to 150,000 asexual parasite count/μl of blood for Parts B and C
- Patients in Part A must weigh between 40 kg and 90 kg. Patients in Part B must weigh between 35 kg and 90 kg at screening. Patients in Part C must weigh at least 10 kg at screening
- Axillary temperature ≥ 37.5ºC or oral/tympanic/rectal temperature ≥ 38.0ºC; or history of fever during the previous 24 hours
Who cannot take part
- Patients with signs and symptoms of severe/complicated malaria at screening or mixed Plasmodium infection (i.e., infection with more than one malaria species) at screening
- Any known/suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection at screening
- Moderate to severe anemia, chronic hemoglobinopathy (Hemoglobin level < 8 g/dL), or known chronic underlying disease such as sickle cell disease at screening
- Known clinically significant liver disease (e.g., chronic hepatitis, liver cirrhosis (compensated or decompensated), history of hepatitis B or C, hepatitis A or B vaccination in the last 3 months, known gallbladder or bile duct disease, acute or chronic pancreatitis. Clinical or laboratory evidence of any of the following at screening:; AST/ALT > 3 x the upper limit of normal range (ULN), regardless of the level of total bilirubin; AST/ALT > 1.5 and ≤ 2 x ULN and total bilirubin is > ULN; Total bilirubin > 2 x ULN, regardless of the level of AST/ALT
- History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study such as:; Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker; History of familial long QT syndrome or known family history of Torsades de Pointe; Resting heart rate (physical exam or 12 lead ECG) < 50 bpm; Other protocol-defined inclusion/exclusion criteria may apply
- Pregnant or nursing (lactating) women, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using methods of effective contraception, and sexually active patients not willing to practice effective contraception
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 100 years old?
This trial has no sites in United States.
It has sites in 6 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria
The 10 groups in the trial
- Cohort A1: Dose Level 1 INE963Treatment being tested
Treatment: INE963
- Cohort A1: Dose Level 2 INE963Treatment being tested
Treatment: INE963
- Cohort A1: Dose Level 3 INE963Treatment being tested
Treatment: INE963
- Cohort B1: Cipargamin + INE963Treatment being tested
Treatment: KAE609 (Cipargamin)
- Cohort B1: SoC (Coartem)Existing treatment, for comparison
Treatment: SoC (Coartem)
- Cohort B2: Cipargamin + KLU156Treatment being tested
Treatment: KAE609 (Cipargamin) and KLU156
- Cohort B2: SoC (Coartem)Existing treatment, for comparison
Treatment: SoC (Coartem)
- Cohort C2: Cipargamin + KLU156Treatment being tested
Treatment: KAE609 (Cipargamin) and KLU156
- Cohort C2: SoC (Coartem)Existing treatment, for comparison
Treatment: SoC (Coartem)
- Cohort A1: Dose Level 4 INE963Treatment being tested
Treatment: INE963
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Patients With Uncomplicated Plasmodium Falciparum Malaria
- Criteria questions
- Built from NCT05750628, who can take part
- Record updated
- 30 July 2025